Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo

Carcinogenesis

Volumn 33, Issue 9, 2012, Pages 1814-1821

  Xie, Hua ^a   Zhu, Feng ^a   Huang, Zunnan ^a   Lee, Mee Hyun ^a   Kim, Dong Joon ^a   Li, Xiang ^a   Lim, Do Young ^a   Jung, Sung Keun ^a   Kang, Soouk ^a   Li, Haitao ^a   Reddy, Kanamata ^a   Wang, Lei ^a   Ma, Weiya ^a   Lubet, Ronald A ^a,b   Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FENRETINIDE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; FENRETINIDE; HUMANS; MICE; PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865574095     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs234     Document Type: Article

References (39)

1. Sogno, I. et al. (2010) Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. Crit. Rev. Oncol. Hematol., 75, 2-14.
2. Abou-Issa, H. et al. (1995) Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res., 15, 805-810.
3. Decensi, A. et al. (1994) Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer. Eur. J. Cancer, 30A, 1909-1910.
4. Zhu, G. et al. (2007) Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer. Oncol. Rep., 18, 645-651.
5. Benelli, R. et al. (2010) The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/ GSK3beta pathway and beta-catenin stability. Mol. Cancer, 9, 142.
6. Lai, W.L. et al. (2008) The PERK/eIF2 alpha signaling pathway of unfolded protein response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells. Exp. Cell Res., 314, 1667-1682.
7. DiPietrantonio, A.M. et al. (1998) Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int. J. Cancer, 78, 53-61.
8. Veronesi, U. et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 91, 1847-1456.
9. Sabichi, A.L. et al. (1998) Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J. Natl. Cancer Inst., 90, 597-605.
10. Lovat, P.E. et al. (2000) Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp. Cell Res., 260, 50-60.
11. Sun, S.Y. et al. (1999) Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res., 59, 2493-2498.
12. Chen, Y.R. et al. (1999) c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Mol. Pharmacol., 56, 1271-1279.
13. Kini, A.R., et al. (2001) Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood, 97, 3919-3924.
14. Pili, R., et al. (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res., 61, 1477-1485.
15. Kim, J.H. et al. (1995) In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma. Anticancer Res., 15, 1429-1434.
16. Simeone, A.M., et al. (2006) N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis, 27, 568-577.
17. Cao, J., et al. (2009) ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic. Biol. Med., 47, 536-547.
18. Rahmaniyan, M. et al. (2011) Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. J. Biol. Chem., 286, 24754-24764.
19. Guertin, D.A. et al. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
20. Hsu, P.P. et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science, 332, 1317-1322.
21. Sarbassov, D.D. et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
22. Liu, P. et al. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 8, 627-644.
23. Choi, J. et al. (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science, 273, 239-242.
24. Yu, K. et al. (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res., 70, 621-631.
25. Wang, X. et al. (2008) Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res., 68, 7409-7418.
26. Gopal, A.K. et al. (2004) Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood, 103, 3516-3520.
27. Formelli, F. et al. (2000) Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. Eur. J. Cancer, 36, 2411-2419.
28. Freedman, V.H. et al. (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell, 3, 355-359.
29. Kiefer, F. et al. (2009) The SWISS-MODEL Repository and associated resources. Nucleic Acids Res., 37, D387-D392.
30. Berndt, A. et al. (2010) The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol., 6, 117-124.
31. Gately, K. et al. (2012) Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer, 75, 217-222.
32. Dobashi, Y., et al. (2009) Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer, 115, 107-118.
33. Dobashi, Y. et al. (2011) Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum. Pathol., 42, 214-226.
34. McDonald, J.M. et al. (2008) Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin. Cancer Res., 14, 7832-7837.
35. Formelli, F. et al. (2008) Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother. Pharmacol., 62, 655-665.
36. Wang, L. et al. (2009) Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. J. Biol. Chem., 284, 14693-14697.
37. Tobak, A. et al. (2007) Construction of the 3D structure of the mTOR kinase-domain and discovery of novel mTOR inhibitors. PhD thesis, Rutgers University.
38. Buck, E. et al. (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res., 68, 8322-8332.
39. Cloughesy, T.F. et al. (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med., 5, e8.